nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfentanil—ABCB1—Mitomycin—urinary bladder cancer	0.197	0.271	CbGbCtD
Alfentanil—ALB—Fluorouracil—urinary bladder cancer	0.0928	0.128	CbGbCtD
Alfentanil—CYP3A4—Thiotepa—urinary bladder cancer	0.0895	0.123	CbGbCtD
Alfentanil—CYP3A5—Etoposide—urinary bladder cancer	0.0622	0.0857	CbGbCtD
Alfentanil—ABCB1—Gemcitabine—urinary bladder cancer	0.0567	0.0781	CbGbCtD
Alfentanil—ALB—Methotrexate—urinary bladder cancer	0.0512	0.0704	CbGbCtD
Alfentanil—ABCB1—Cisplatin—urinary bladder cancer	0.0412	0.0567	CbGbCtD
Alfentanil—ABCB1—Etoposide—urinary bladder cancer	0.0405	0.0558	CbGbCtD
Alfentanil—ABCB1—Doxorubicin—urinary bladder cancer	0.0276	0.038	CbGbCtD
Alfentanil—ABCB1—Methotrexate—urinary bladder cancer	0.0268	0.0368	CbGbCtD
Alfentanil—CYP3A4—Etoposide—urinary bladder cancer	0.0243	0.0334	CbGbCtD
Alfentanil—CYP3A4—Doxorubicin—urinary bladder cancer	0.0166	0.0228	CbGbCtD
Alfentanil—Erythema—Fluorouracil—urinary bladder cancer	0.000829	0.0035	CcSEcCtD
Alfentanil—Confusional state—Thiotepa—urinary bladder cancer	0.000824	0.00348	CcSEcCtD
Alfentanil—Immune system disorder—Cisplatin—urinary bladder cancer	0.000815	0.00344	CcSEcCtD
Alfentanil—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000813	0.00344	CcSEcCtD
Alfentanil—Arrhythmia—Cisplatin—urinary bladder cancer	0.000806	0.00341	CcSEcCtD
Alfentanil—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000802	0.00339	CcSEcCtD
Alfentanil—Tachycardia—Thiotepa—urinary bladder cancer	0.000798	0.00337	CcSEcCtD
Alfentanil—Skin disorder—Thiotepa—urinary bladder cancer	0.000794	0.00336	CcSEcCtD
Alfentanil—Erythema—Cisplatin—urinary bladder cancer	0.000786	0.00332	CcSEcCtD
Alfentanil—Vision blurred—Fluorouracil—urinary bladder cancer	0.000781	0.0033	CcSEcCtD
Alfentanil—Eye disorder—Etoposide—urinary bladder cancer	0.000773	0.00327	CcSEcCtD
Alfentanil—Cardiac disorder—Etoposide—urinary bladder cancer	0.000767	0.00324	CcSEcCtD
Alfentanil—Visual disturbance—Methotrexate—urinary bladder cancer	0.000755	0.00319	CcSEcCtD
Alfentanil—Angiopathy—Etoposide—urinary bladder cancer	0.00075	0.00317	CcSEcCtD
Alfentanil—Immune system disorder—Etoposide—urinary bladder cancer	0.000747	0.00316	CcSEcCtD
Alfentanil—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000745	0.00315	CcSEcCtD
Alfentanil—Chills—Etoposide—urinary bladder cancer	0.000742	0.00313	CcSEcCtD
Alfentanil—Vision blurred—Cisplatin—urinary bladder cancer	0.00074	0.00313	CcSEcCtD
Alfentanil—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.00074	0.00313	CcSEcCtD
Alfentanil—Cough—Gemcitabine—urinary bladder cancer	0.000735	0.00311	CcSEcCtD
Alfentanil—Hypertension—Gemcitabine—urinary bladder cancer	0.000728	0.00308	CcSEcCtD
Alfentanil—Somnolence—Thiotepa—urinary bladder cancer	0.000727	0.00307	CcSEcCtD
Alfentanil—Convulsion—Fluorouracil—urinary bladder cancer	0.000718	0.00303	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000713	0.00301	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000706	0.00298	CcSEcCtD
Alfentanil—Fatigue—Thiotepa—urinary bladder cancer	0.000705	0.00298	CcSEcCtD
Alfentanil—Pain—Thiotepa—urinary bladder cancer	0.000699	0.00296	CcSEcCtD
Alfentanil—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000692	0.00293	CcSEcCtD
Alfentanil—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000688	0.00291	CcSEcCtD
Alfentanil—Confusional state—Fluorouracil—urinary bladder cancer	0.000682	0.00288	CcSEcCtD
Alfentanil—Convulsion—Cisplatin—urinary bladder cancer	0.000681	0.00288	CcSEcCtD
Alfentanil—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000676	0.00286	CcSEcCtD
Alfentanil—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000675	0.00285	CcSEcCtD
Alfentanil—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000674	0.00285	CcSEcCtD
Alfentanil—Skin disorder—Gemcitabine—urinary bladder cancer	0.000668	0.00282	CcSEcCtD
Alfentanil—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000665	0.00281	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000664	0.00281	CcSEcCtD
Alfentanil—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000663	0.0028	CcSEcCtD
Alfentanil—Tachycardia—Fluorouracil—urinary bladder cancer	0.00066	0.00279	CcSEcCtD
Alfentanil—Urticaria—Thiotepa—urinary bladder cancer	0.00065	0.00275	CcSEcCtD
Alfentanil—Body temperature increased—Thiotepa—urinary bladder cancer	0.000646	0.00273	CcSEcCtD
Alfentanil—Hypotension—Gemcitabine—urinary bladder cancer	0.000643	0.00272	CcSEcCtD
Alfentanil—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000641	0.00271	CcSEcCtD
Alfentanil—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.00064	0.00271	CcSEcCtD
Alfentanil—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000637	0.00269	CcSEcCtD
Alfentanil—Loss of consciousness—Etoposide—urinary bladder cancer	0.000633	0.00267	CcSEcCtD
Alfentanil—Hypotension—Fluorouracil—urinary bladder cancer	0.000632	0.00267	CcSEcCtD
Alfentanil—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000629	0.00266	CcSEcCtD
Alfentanil—Cough—Etoposide—urinary bladder cancer	0.000628	0.00265	CcSEcCtD
Alfentanil—Tachycardia—Cisplatin—urinary bladder cancer	0.000626	0.00264	CcSEcCtD
Alfentanil—Convulsion—Etoposide—urinary bladder cancer	0.000624	0.00264	CcSEcCtD
Alfentanil—Skin disorder—Cisplatin—urinary bladder cancer	0.000623	0.00263	CcSEcCtD
Alfentanil—Hypertension—Etoposide—urinary bladder cancer	0.000621	0.00263	CcSEcCtD
Alfentanil—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00062	0.00262	CcSEcCtD
Alfentanil—Somnolence—Gemcitabine—urinary bladder cancer	0.000612	0.00258	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000608	0.00257	CcSEcCtD
Alfentanil—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000602	0.00255	CcSEcCtD
Alfentanil—Somnolence—Fluorouracil—urinary bladder cancer	0.000601	0.00254	CcSEcCtD
Alfentanil—Hypotension—Cisplatin—urinary bladder cancer	0.000599	0.00253	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000594	0.00251	CcSEcCtD
Alfentanil—Fatigue—Gemcitabine—urinary bladder cancer	0.000593	0.00251	CcSEcCtD
Alfentanil—Confusional state—Etoposide—urinary bladder cancer	0.000592	0.0025	CcSEcCtD
Alfentanil—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000589	0.00249	CcSEcCtD
Alfentanil—Pain—Gemcitabine—urinary bladder cancer	0.000588	0.00249	CcSEcCtD
Alfentanil—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000587	0.00248	CcSEcCtD
Alfentanil—Asthenia—Thiotepa—urinary bladder cancer	0.000587	0.00248	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000584	0.00247	CcSEcCtD
Alfentanil—Pruritus—Thiotepa—urinary bladder cancer	0.000579	0.00244	CcSEcCtD
Alfentanil—Pain—Fluorouracil—urinary bladder cancer	0.000578	0.00244	CcSEcCtD
Alfentanil—Tachycardia—Etoposide—urinary bladder cancer	0.000573	0.00242	CcSEcCtD
Alfentanil—Skin disorder—Etoposide—urinary bladder cancer	0.000571	0.00241	CcSEcCtD
Alfentanil—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000568	0.0024	CcSEcCtD
Alfentanil—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000567	0.0024	CcSEcCtD
Alfentanil—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000557	0.00236	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000554	0.00234	CcSEcCtD
Alfentanil—Drowsiness—Methotrexate—urinary bladder cancer	0.000552	0.00233	CcSEcCtD
Alfentanil—Hypotension—Etoposide—urinary bladder cancer	0.000549	0.00232	CcSEcCtD
Alfentanil—Pain—Cisplatin—urinary bladder cancer	0.000548	0.00232	CcSEcCtD
Alfentanil—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000544	0.0023	CcSEcCtD
Alfentanil—Dizziness—Thiotepa—urinary bladder cancer	0.000541	0.00229	CcSEcCtD
Alfentanil—Urticaria—Fluorouracil—urinary bladder cancer	0.000537	0.00227	CcSEcCtD
Alfentanil—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000535	0.00226	CcSEcCtD
Alfentanil—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000528	0.00223	CcSEcCtD
Alfentanil—Somnolence—Etoposide—urinary bladder cancer	0.000522	0.00221	CcSEcCtD
Alfentanil—Epistaxis—Methotrexate—urinary bladder cancer	0.00052	0.0022	CcSEcCtD
Alfentanil—Vomiting—Thiotepa—urinary bladder cancer	0.00052	0.0022	CcSEcCtD
Alfentanil—Drowsiness—Epirubicin—urinary bladder cancer	0.000516	0.00218	CcSEcCtD
Alfentanil—Rash—Thiotepa—urinary bladder cancer	0.000516	0.00218	CcSEcCtD
Alfentanil—Dermatitis—Thiotepa—urinary bladder cancer	0.000515	0.00218	CcSEcCtD
Alfentanil—Headache—Thiotepa—urinary bladder cancer	0.000512	0.00216	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000507	0.00214	CcSEcCtD
Alfentanil—Body temperature increased—Cisplatin—urinary bladder cancer	0.000507	0.00214	CcSEcCtD
Alfentanil—Fatigue—Etoposide—urinary bladder cancer	0.000506	0.00214	CcSEcCtD
Alfentanil—Pain—Etoposide—urinary bladder cancer	0.000502	0.00212	CcSEcCtD
Alfentanil—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000498	0.00211	CcSEcCtD
Alfentanil—Asthenia—Gemcitabine—urinary bladder cancer	0.000494	0.00209	CcSEcCtD
Alfentanil—Epistaxis—Epirubicin—urinary bladder cancer	0.000487	0.00206	CcSEcCtD
Alfentanil—Pruritus—Gemcitabine—urinary bladder cancer	0.000487	0.00206	CcSEcCtD
Alfentanil—Nausea—Thiotepa—urinary bladder cancer	0.000486	0.00205	CcSEcCtD
Alfentanil—Feeling abnormal—Etoposide—urinary bladder cancer	0.000484	0.00205	CcSEcCtD
Alfentanil—Pruritus—Fluorouracil—urinary bladder cancer	0.000478	0.00202	CcSEcCtD
Alfentanil—Drowsiness—Doxorubicin—urinary bladder cancer	0.000478	0.00202	CcSEcCtD
Alfentanil—Visual impairment—Methotrexate—urinary bladder cancer	0.000477	0.00202	CcSEcCtD
Alfentanil—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000472	0.002	CcSEcCtD
Alfentanil—Bradycardia—Epirubicin—urinary bladder cancer	0.000472	0.00199	CcSEcCtD
Alfentanil—Urticaria—Etoposide—urinary bladder cancer	0.000467	0.00197	CcSEcCtD
Alfentanil—Body temperature increased—Etoposide—urinary bladder cancer	0.000464	0.00196	CcSEcCtD
Alfentanil—Eye disorder—Methotrexate—urinary bladder cancer	0.000463	0.00196	CcSEcCtD
Alfentanil—Asthenia—Cisplatin—urinary bladder cancer	0.00046	0.00194	CcSEcCtD
Alfentanil—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00046	0.00194	CcSEcCtD
Alfentanil—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000455	0.00192	CcSEcCtD
Alfentanil—Epistaxis—Doxorubicin—urinary bladder cancer	0.000451	0.0019	CcSEcCtD
Alfentanil—Angiopathy—Methotrexate—urinary bladder cancer	0.000449	0.0019	CcSEcCtD
Alfentanil—Immune system disorder—Methotrexate—urinary bladder cancer	0.000447	0.00189	CcSEcCtD
Alfentanil—Dizziness—Fluorouracil—urinary bladder cancer	0.000447	0.00189	CcSEcCtD
Alfentanil—Visual impairment—Epirubicin—urinary bladder cancer	0.000447	0.00189	CcSEcCtD
Alfentanil—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000446	0.00189	CcSEcCtD
Alfentanil—Chills—Methotrexate—urinary bladder cancer	0.000444	0.00188	CcSEcCtD
Alfentanil—Vomiting—Gemcitabine—urinary bladder cancer	0.000437	0.00185	CcSEcCtD
Alfentanil—Bradycardia—Doxorubicin—urinary bladder cancer	0.000437	0.00184	CcSEcCtD
Alfentanil—Mental disorder—Methotrexate—urinary bladder cancer	0.000434	0.00183	CcSEcCtD
Alfentanil—Rash—Gemcitabine—urinary bladder cancer	0.000434	0.00183	CcSEcCtD
Alfentanil—Dermatitis—Gemcitabine—urinary bladder cancer	0.000433	0.00183	CcSEcCtD
Alfentanil—Eye disorder—Epirubicin—urinary bladder cancer	0.000433	0.00183	CcSEcCtD
Alfentanil—Hypersensitivity—Etoposide—urinary bladder cancer	0.000433	0.00183	CcSEcCtD
Alfentanil—Erythema—Methotrexate—urinary bladder cancer	0.000431	0.00182	CcSEcCtD
Alfentanil—Headache—Gemcitabine—urinary bladder cancer	0.000431	0.00182	CcSEcCtD
Alfentanil—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00043	0.00182	CcSEcCtD
Alfentanil—Vomiting—Fluorouracil—urinary bladder cancer	0.00043	0.00182	CcSEcCtD
Alfentanil—Rash—Fluorouracil—urinary bladder cancer	0.000426	0.0018	CcSEcCtD
Alfentanil—Dermatitis—Fluorouracil—urinary bladder cancer	0.000426	0.0018	CcSEcCtD
Alfentanil—Headache—Fluorouracil—urinary bladder cancer	0.000424	0.00179	CcSEcCtD
Alfentanil—Asthenia—Etoposide—urinary bladder cancer	0.000421	0.00178	CcSEcCtD
Alfentanil—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000421	0.00178	CcSEcCtD
Alfentanil—Angiopathy—Epirubicin—urinary bladder cancer	0.00042	0.00178	CcSEcCtD
Alfentanil—Immune system disorder—Epirubicin—urinary bladder cancer	0.000419	0.00177	CcSEcCtD
Alfentanil—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000418	0.00177	CcSEcCtD
Alfentanil—Chills—Epirubicin—urinary bladder cancer	0.000416	0.00176	CcSEcCtD
Alfentanil—Pruritus—Etoposide—urinary bladder cancer	0.000416	0.00176	CcSEcCtD
Alfentanil—Arrhythmia—Epirubicin—urinary bladder cancer	0.000414	0.00175	CcSEcCtD
Alfentanil—Visual impairment—Doxorubicin—urinary bladder cancer	0.000413	0.00175	CcSEcCtD
Alfentanil—Nausea—Gemcitabine—urinary bladder cancer	0.000409	0.00173	CcSEcCtD
Alfentanil—Vomiting—Cisplatin—urinary bladder cancer	0.000408	0.00172	CcSEcCtD
Alfentanil—Vision blurred—Methotrexate—urinary bladder cancer	0.000406	0.00172	CcSEcCtD
Alfentanil—Mental disorder—Epirubicin—urinary bladder cancer	0.000406	0.00172	CcSEcCtD
Alfentanil—Rash—Cisplatin—urinary bladder cancer	0.000404	0.00171	CcSEcCtD
Alfentanil—Dermatitis—Cisplatin—urinary bladder cancer	0.000404	0.00171	CcSEcCtD
Alfentanil—Erythema—Epirubicin—urinary bladder cancer	0.000403	0.0017	CcSEcCtD
Alfentanil—Nausea—Fluorouracil—urinary bladder cancer	0.000402	0.0017	CcSEcCtD
Alfentanil—Eye disorder—Doxorubicin—urinary bladder cancer	0.000401	0.00169	CcSEcCtD
Alfentanil—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000398	0.00168	CcSEcCtD
Alfentanil—Angiopathy—Doxorubicin—urinary bladder cancer	0.000389	0.00164	CcSEcCtD
Alfentanil—Dizziness—Etoposide—urinary bladder cancer	0.000388	0.00164	CcSEcCtD
Alfentanil—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000387	0.00164	CcSEcCtD
Alfentanil—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000386	0.00163	CcSEcCtD
Alfentanil—Chills—Doxorubicin—urinary bladder cancer	0.000385	0.00163	CcSEcCtD
Alfentanil—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000383	0.00162	CcSEcCtD
Alfentanil—Nausea—Cisplatin—urinary bladder cancer	0.000381	0.00161	CcSEcCtD
Alfentanil—Vision blurred—Epirubicin—urinary bladder cancer	0.00038	0.00161	CcSEcCtD
Alfentanil—Cough—Methotrexate—urinary bladder cancer	0.000376	0.00159	CcSEcCtD
Alfentanil—Mental disorder—Doxorubicin—urinary bladder cancer	0.000376	0.00159	CcSEcCtD
Alfentanil—Convulsion—Methotrexate—urinary bladder cancer	0.000374	0.00158	CcSEcCtD
Alfentanil—Vomiting—Etoposide—urinary bladder cancer	0.000373	0.00158	CcSEcCtD
Alfentanil—Erythema—Doxorubicin—urinary bladder cancer	0.000373	0.00158	CcSEcCtD
Alfentanil—Agitation—Epirubicin—urinary bladder cancer	0.000371	0.00157	CcSEcCtD
Alfentanil—Rash—Etoposide—urinary bladder cancer	0.00037	0.00157	CcSEcCtD
Alfentanil—Dermatitis—Etoposide—urinary bladder cancer	0.00037	0.00156	CcSEcCtD
Alfentanil—Headache—Etoposide—urinary bladder cancer	0.000368	0.00156	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000364	0.00154	CcSEcCtD
Alfentanil—Confusional state—Methotrexate—urinary bladder cancer	0.000355	0.0015	CcSEcCtD
Alfentanil—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000355	0.0015	CcSEcCtD
Alfentanil—Cough—Epirubicin—urinary bladder cancer	0.000352	0.00149	CcSEcCtD
Alfentanil—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000352	0.00149	CcSEcCtD
Alfentanil—Vision blurred—Doxorubicin—urinary bladder cancer	0.000352	0.00149	CcSEcCtD
Alfentanil—Convulsion—Epirubicin—urinary bladder cancer	0.00035	0.00148	CcSEcCtD
Alfentanil—Nausea—Etoposide—urinary bladder cancer	0.000349	0.00147	CcSEcCtD
Alfentanil—Hypertension—Epirubicin—urinary bladder cancer	0.000348	0.00147	CcSEcCtD
Alfentanil—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000345	0.00146	CcSEcCtD
Alfentanil—Agitation—Doxorubicin—urinary bladder cancer	0.000343	0.00145	CcSEcCtD
Alfentanil—Skin disorder—Methotrexate—urinary bladder cancer	0.000342	0.00144	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000341	0.00144	CcSEcCtD
Alfentanil—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00034	0.00144	CcSEcCtD
Alfentanil—Confusional state—Epirubicin—urinary bladder cancer	0.000332	0.0014	CcSEcCtD
Alfentanil—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000329	0.00139	CcSEcCtD
Alfentanil—Hypotension—Methotrexate—urinary bladder cancer	0.000329	0.00139	CcSEcCtD
Alfentanil—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000328	0.00139	CcSEcCtD
Alfentanil—Cough—Doxorubicin—urinary bladder cancer	0.000326	0.00138	CcSEcCtD
Alfentanil—Convulsion—Doxorubicin—urinary bladder cancer	0.000323	0.00137	CcSEcCtD
Alfentanil—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000323	0.00136	CcSEcCtD
Alfentanil—Hypertension—Doxorubicin—urinary bladder cancer	0.000322	0.00136	CcSEcCtD
Alfentanil—Tachycardia—Epirubicin—urinary bladder cancer	0.000321	0.00136	CcSEcCtD
Alfentanil—Skin disorder—Epirubicin—urinary bladder cancer	0.00032	0.00135	CcSEcCtD
Alfentanil—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000318	0.00135	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000316	0.00133	CcSEcCtD
Alfentanil—Somnolence—Methotrexate—urinary bladder cancer	0.000313	0.00132	CcSEcCtD
Alfentanil—Hypotension—Epirubicin—urinary bladder cancer	0.000308	0.0013	CcSEcCtD
Alfentanil—Confusional state—Doxorubicin—urinary bladder cancer	0.000307	0.0013	CcSEcCtD
Alfentanil—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000305	0.00129	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000304	0.00128	CcSEcCtD
Alfentanil—Fatigue—Methotrexate—urinary bladder cancer	0.000303	0.00128	CcSEcCtD
Alfentanil—Pain—Methotrexate—urinary bladder cancer	0.000301	0.00127	CcSEcCtD
Alfentanil—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000299	0.00126	CcSEcCtD
Alfentanil—Tachycardia—Doxorubicin—urinary bladder cancer	0.000297	0.00126	CcSEcCtD
Alfentanil—Skin disorder—Doxorubicin—urinary bladder cancer	0.000296	0.00125	CcSEcCtD
Alfentanil—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000295	0.00124	CcSEcCtD
Alfentanil—Somnolence—Epirubicin—urinary bladder cancer	0.000293	0.00124	CcSEcCtD
Alfentanil—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00029	0.00123	CcSEcCtD
Alfentanil—Hypotension—Doxorubicin—urinary bladder cancer	0.000285	0.0012	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000284	0.0012	CcSEcCtD
Alfentanil—Fatigue—Epirubicin—urinary bladder cancer	0.000284	0.0012	CcSEcCtD
Alfentanil—Pain—Epirubicin—urinary bladder cancer	0.000282	0.00119	CcSEcCtD
Alfentanil—Urticaria—Methotrexate—urinary bladder cancer	0.000279	0.00118	CcSEcCtD
Alfentanil—Body temperature increased—Methotrexate—urinary bladder cancer	0.000278	0.00118	CcSEcCtD
Alfentanil—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000271	0.00115	CcSEcCtD
Alfentanil—Somnolence—Doxorubicin—urinary bladder cancer	0.000271	0.00114	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000263	0.00111	CcSEcCtD
Alfentanil—Fatigue—Doxorubicin—urinary bladder cancer	0.000263	0.00111	CcSEcCtD
Alfentanil—Urticaria—Epirubicin—urinary bladder cancer	0.000262	0.00111	CcSEcCtD
Alfentanil—Pain—Doxorubicin—urinary bladder cancer	0.000261	0.0011	CcSEcCtD
Alfentanil—Body temperature increased—Epirubicin—urinary bladder cancer	0.00026	0.0011	CcSEcCtD
Alfentanil—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000259	0.0011	CcSEcCtD
Alfentanil—Asthenia—Methotrexate—urinary bladder cancer	0.000252	0.00107	CcSEcCtD
Alfentanil—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000251	0.00106	CcSEcCtD
Alfentanil—Pruritus—Methotrexate—urinary bladder cancer	0.000249	0.00105	CcSEcCtD
Alfentanil—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000243	0.00103	CcSEcCtD
Alfentanil—Urticaria—Doxorubicin—urinary bladder cancer	0.000242	0.00102	CcSEcCtD
Alfentanil—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000241	0.00102	CcSEcCtD
Alfentanil—Asthenia—Epirubicin—urinary bladder cancer	0.000236	0.000998	CcSEcCtD
Alfentanil—Pruritus—Epirubicin—urinary bladder cancer	0.000233	0.000984	CcSEcCtD
Alfentanil—Dizziness—Methotrexate—urinary bladder cancer	0.000233	0.000983	CcSEcCtD
Alfentanil—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000224	0.000949	CcSEcCtD
Alfentanil—Vomiting—Methotrexate—urinary bladder cancer	0.000224	0.000945	CcSEcCtD
Alfentanil—Rash—Methotrexate—urinary bladder cancer	0.000222	0.000937	CcSEcCtD
Alfentanil—Dermatitis—Methotrexate—urinary bladder cancer	0.000222	0.000937	CcSEcCtD
Alfentanil—Headache—Methotrexate—urinary bladder cancer	0.00022	0.000931	CcSEcCtD
Alfentanil—Asthenia—Doxorubicin—urinary bladder cancer	0.000219	0.000924	CcSEcCtD
Alfentanil—Dizziness—Epirubicin—urinary bladder cancer	0.000218	0.00092	CcSEcCtD
Alfentanil—Pruritus—Doxorubicin—urinary bladder cancer	0.000216	0.000911	CcSEcCtD
Alfentanil—Vomiting—Epirubicin—urinary bladder cancer	0.000209	0.000885	CcSEcCtD
Alfentanil—Nausea—Methotrexate—urinary bladder cancer	0.000209	0.000883	CcSEcCtD
Alfentanil—Rash—Epirubicin—urinary bladder cancer	0.000208	0.000877	CcSEcCtD
Alfentanil—Dermatitis—Epirubicin—urinary bladder cancer	0.000207	0.000877	CcSEcCtD
Alfentanil—Headache—Epirubicin—urinary bladder cancer	0.000206	0.000872	CcSEcCtD
Alfentanil—Dizziness—Doxorubicin—urinary bladder cancer	0.000201	0.000851	CcSEcCtD
Alfentanil—Nausea—Epirubicin—urinary bladder cancer	0.000196	0.000826	CcSEcCtD
Alfentanil—Vomiting—Doxorubicin—urinary bladder cancer	0.000194	0.000819	CcSEcCtD
Alfentanil—Rash—Doxorubicin—urinary bladder cancer	0.000192	0.000812	CcSEcCtD
Alfentanil—Dermatitis—Doxorubicin—urinary bladder cancer	0.000192	0.000811	CcSEcCtD
Alfentanil—Headache—Doxorubicin—urinary bladder cancer	0.000191	0.000807	CcSEcCtD
Alfentanil—Nausea—Doxorubicin—urinary bladder cancer	0.000181	0.000765	CcSEcCtD
Alfentanil—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	8.52e-05	0.00231	CbGpPWpGaD
Alfentanil—ALB—Platelet degranulation—IGF1—urinary bladder cancer	8.46e-05	0.00229	CbGpPWpGaD
Alfentanil—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.4e-05	0.00228	CbGpPWpGaD
Alfentanil—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	8.06e-05	0.00219	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	7.97e-05	0.00216	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	7.88e-05	0.00214	CbGpPWpGaD
Alfentanil—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	7.83e-05	0.00212	CbGpPWpGaD
Alfentanil—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.72e-05	0.00209	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—IL2—urinary bladder cancer	7.58e-05	0.00206	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	7.37e-05	0.002	CbGpPWpGaD
Alfentanil—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	7.27e-05	0.00197	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	7.22e-05	0.00196	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	7.04e-05	0.00191	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	6.85e-05	0.00186	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—NAT1—urinary bladder cancer	6.85e-05	0.00186	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	6.79e-05	0.00184	CbGpPWpGaD
Alfentanil—OPRM1—TCR Signaling Pathway—HRAS—urinary bladder cancer	6.79e-05	0.00184	CbGpPWpGaD
Alfentanil—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	6.59e-05	0.00179	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	6.58e-05	0.00178	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	6.5e-05	0.00176	CbGpPWpGaD
Alfentanil—OPRM1—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	6.36e-05	0.00172	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	6.26e-05	0.0017	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	6.02e-05	0.00163	CbGpPWpGaD
Alfentanil—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	5.96e-05	0.00162	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	5.89e-05	0.0016	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	5.76e-05	0.00156	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	5.75e-05	0.00156	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	5.72e-05	0.00155	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	5.64e-05	0.00153	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.6e-05	0.00152	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—TNF—urinary bladder cancer	5.52e-05	0.0015	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.5e-05	0.00149	CbGpPWpGaD
Alfentanil—OPRM1—G alpha (i) signalling events—CXCL8—urinary bladder cancer	5.37e-05	0.00145	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.36e-05	0.00145	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	5.32e-05	0.00144	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	5.22e-05	0.00142	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	5.19e-05	0.00141	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	4.95e-05	0.00134	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—NAT1—urinary bladder cancer	4.95e-05	0.00134	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	4.87e-05	0.00132	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—TP53—urinary bladder cancer	4.87e-05	0.00132	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—HDAC4—urinary bladder cancer	4.81e-05	0.0013	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.7e-05	0.00127	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	4.53e-05	0.00123	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GSTZ1—urinary bladder cancer	4.5e-05	0.00122	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	4.39e-05	0.00119	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.3e-05	0.00117	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.29e-05	0.00116	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.27e-05	0.00116	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	4.27e-05	0.00116	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GSTO2—urinary bladder cancer	4.26e-05	0.00116	CbGpPWpGaD
Alfentanil—ALB—Metabolism—NAT1—urinary bladder cancer	4.26e-05	0.00116	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.19e-05	0.00114	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	4.19e-05	0.00114	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—TYMP—urinary bladder cancer	4.15e-05	0.00112	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	4.08e-05	0.00111	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—GLI1—urinary bladder cancer	4.03e-05	0.00109	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.96e-05	0.00107	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	3.94e-05	0.00107	CbGpPWpGaD
Alfentanil—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.91e-05	0.00106	CbGpPWpGaD
Alfentanil—ALB—Metabolism—UGT2B7—urinary bladder cancer	3.9e-05	0.00106	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	3.85e-05	0.00104	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	3.75e-05	0.00102	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—NAT2—urinary bladder cancer	3.75e-05	0.00102	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	3.75e-05	0.00102	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.74e-05	0.00101	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GSTO2—urinary bladder cancer	3.73e-05	0.00101	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—NAT1—urinary bladder cancer	3.73e-05	0.00101	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.69e-05	0.001	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.64e-05	0.000987	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.62e-05	0.000982	CbGpPWpGaD
Alfentanil—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.59e-05	0.000974	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CYP4B1—urinary bladder cancer	3.51e-05	0.000952	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	3.44e-05	0.000932	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	3.42e-05	0.000926	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—IFNA2—urinary bladder cancer	3.35e-05	0.000907	CbGpPWpGaD
Alfentanil—ALB—Metabolism—SLC19A1—urinary bladder cancer	3.31e-05	0.000899	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CXCL8—urinary bladder cancer	3.25e-05	0.000881	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—RRM2—urinary bladder cancer	3.24e-05	0.000878	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PRSS3—urinary bladder cancer	3.23e-05	0.000876	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.17e-05	0.000861	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.13e-05	0.00085	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.08e-05	0.000834	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.06e-05	0.000831	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	3e-05	0.000813	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—ENO2—urinary bladder cancer	3e-05	0.000813	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—TYMP—urinary bladder cancer	3e-05	0.000813	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	2.91e-05	0.000789	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.9e-05	0.000787	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	2.88e-05	0.000782	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.83e-05	0.000767	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.77e-05	0.000751	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—RBX1—urinary bladder cancer	2.76e-05	0.000749	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—NAT2—urinary bladder cancer	2.71e-05	0.000735	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.68e-05	0.000726	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.67e-05	0.000724	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TSC1—urinary bladder cancer	2.6e-05	0.000705	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.59e-05	0.000702	CbGpPWpGaD
Alfentanil—ALB—Metabolism—TYMP—urinary bladder cancer	2.58e-05	0.0007	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.55e-05	0.000691	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	2.52e-05	0.000682	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.48e-05	0.000672	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.48e-05	0.000672	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—JAG1—urinary bladder cancer	2.47e-05	0.000671	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.43e-05	0.000658	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—NQO1—urinary bladder cancer	2.42e-05	0.000655	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—PLAU—urinary bladder cancer	2.37e-05	0.000644	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—RRM2—urinary bladder cancer	2.34e-05	0.000635	CbGpPWpGaD
Alfentanil—ALB—Metabolism—NAT2—urinary bladder cancer	2.34e-05	0.000633	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.3e-05	0.000624	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.3e-05	0.000624	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.26e-05	0.000613	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.22e-05	0.000602	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.17e-05	0.000589	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.17e-05	0.000588	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.17e-05	0.000588	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.1e-05	0.000571	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	2.1e-05	0.00057	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	2.09e-05	0.000567	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.07e-05	0.000561	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.05e-05	0.000556	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.05e-05	0.000555	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	2.02e-05	0.000547	CbGpPWpGaD
Alfentanil—ALB—Metabolism—RRM2—urinary bladder cancer	2.02e-05	0.000547	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—S100B—urinary bladder cancer	2e-05	0.000543	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.96e-05	0.000531	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—IGF1—urinary bladder cancer	1.93e-05	0.000524	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—RHOA—urinary bladder cancer	1.9e-05	0.000515	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.89e-05	0.000514	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—TYMS—urinary bladder cancer	1.87e-05	0.000508	CbGpPWpGaD
Alfentanil—ALB—Metabolism—ENO2—urinary bladder cancer	1.87e-05	0.000506	CbGpPWpGaD
Alfentanil—ALB—Metabolism—HPGDS—urinary bladder cancer	1.87e-05	0.000506	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.86e-05	0.000503	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	1.85e-05	0.000502	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	1.85e-05	0.000502	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.84e-05	0.000498	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.82e-05	0.000494	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GSTT1—urinary bladder cancer	1.81e-05	0.000491	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—NCOR1—urinary bladder cancer	1.8e-05	0.000488	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.79e-05	0.000485	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.78e-05	0.000483	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GPX1—urinary bladder cancer	1.77e-05	0.000481	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—RHOA—urinary bladder cancer	1.77e-05	0.00048	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.77e-05	0.000479	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—IL2—urinary bladder cancer	1.75e-05	0.000476	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.75e-05	0.000474	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.74e-05	0.000473	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.74e-05	0.000472	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.7e-05	0.00046	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.67e-05	0.000452	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.64e-05	0.000444	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.64e-05	0.000444	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.64e-05	0.000444	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.59e-05	0.000432	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TERT—urinary bladder cancer	1.59e-05	0.00043	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.59e-05	0.00043	CbGpPWpGaD
Alfentanil—ALB—Metabolism—NQO1—urinary bladder cancer	1.5e-05	0.000408	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—IL2—urinary bladder cancer	1.49e-05	0.000403	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.49e-05	0.000403	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.46e-05	0.000396	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.46e-05	0.000395	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.46e-05	0.000395	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—ESR1—urinary bladder cancer	1.41e-05	0.000384	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.39e-05	0.000378	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.35e-05	0.000367	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.34e-05	0.000363	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.34e-05	0.000363	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—EP300—urinary bladder cancer	1.33e-05	0.000362	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.33e-05	0.00036	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.32e-05	0.000358	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—SRC—urinary bladder cancer	1.3e-05	0.000352	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.28e-05	0.000348	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.28e-05	0.000346	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.27e-05	0.000345	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.26e-05	0.000342	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.26e-05	0.000341	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GSTP1—urinary bladder cancer	1.26e-05	0.00034	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CREBBP—urinary bladder cancer	1.24e-05	0.000336	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IGF1—urinary bladder cancer	1.22e-05	0.000332	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—EGFR—urinary bladder cancer	1.22e-05	0.00033	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.21e-05	0.000329	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.18e-05	0.000321	CbGpPWpGaD
Alfentanil—ALB—Metabolism—TYMS—urinary bladder cancer	1.17e-05	0.000316	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	0.000313	CbGpPWpGaD
Alfentanil—ALB—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	0.000313	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—KRAS—urinary bladder cancer	1.15e-05	0.000312	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—RHOA—urinary bladder cancer	1.12e-05	0.000304	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GPX1—urinary bladder cancer	1.1e-05	0.000299	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.1e-05	0.000298	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.09e-05	0.000295	CbGpPWpGaD
Alfentanil—ALB—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	0.000294	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—KRAS—urinary bladder cancer	1.07e-05	0.000291	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.04e-05	0.000283	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.04e-05	0.000282	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.02e-05	0.000277	CbGpPWpGaD
Alfentanil—ALB—Metabolism—MTHFR—urinary bladder cancer	1.02e-05	0.000276	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.01e-05	0.000274	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.01e-05	0.000274	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.01e-05	0.000273	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.01e-05	0.000273	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	9.85e-06	0.000267	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	9.78e-06	0.000265	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.77e-06	0.000265	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.68e-06	0.000262	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PPARG—urinary bladder cancer	9.6e-06	0.00026	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—TP53—urinary bladder cancer	9.54e-06	0.000259	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ERCC2—urinary bladder cancer	9.5e-06	0.000258	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	9.41e-06	0.000255	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	9.22e-06	0.00025	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	9.18e-06	0.000249	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—HRAS—urinary bladder cancer	9.13e-06	0.000248	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PTEN—urinary bladder cancer	9.11e-06	0.000247	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.93e-06	0.000242	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	8.91e-06	0.000242	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.88e-06	0.000241	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	8.86e-06	0.00024	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—EP300—urinary bladder cancer	8.69e-06	0.000236	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	8.45e-06	0.000229	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PPARG—urinary bladder cancer	8.27e-06	0.000224	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	8.21e-06	0.000223	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.12e-06	0.00022	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CREBBP—urinary bladder cancer	7.94e-06	0.000215	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	7.55e-06	0.000205	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	7.36e-06	0.0002	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.24e-06	0.000196	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	7.2e-06	0.000195	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.96e-06	0.000189	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	6.8e-06	0.000184	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.78e-06	0.000184	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PTEN—urinary bladder cancer	6.58e-06	0.000179	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PTGS2—urinary bladder cancer	6.5e-06	0.000176	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.3e-06	0.000171	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—EP300—urinary bladder cancer	6.28e-06	0.00017	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.23e-06	0.000169	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.23e-06	0.000169	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	6.04e-06	0.000164	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.96e-06	0.000162	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.85e-06	0.000159	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	5.78e-06	0.000157	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.7e-06	0.000154	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PTEN—urinary bladder cancer	5.67e-06	0.000154	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.5e-06	0.000149	CbGpPWpGaD
Alfentanil—ALB—Metabolism—EP300—urinary bladder cancer	5.41e-06	0.000147	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.97e-06	0.000135	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—EP300—urinary bladder cancer	4.74e-06	0.000128	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.46e-06	0.000121	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.29e-06	0.000116	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.51e-06	9.52e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.06e-06	8.3e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.92e-06	7.92e-05	CbGpPWpGaD
